Liposome Drug Delivery Market Report 2023 (Global Edition)

Global Liposome Drug Delivery Market Report 2023 talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Liposome Drug Delivery Industry growth. Liposome Drug Delivery market has been segmented with the help of its Product, Application , and others. Liposome Drug Delivery market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.

Report scope is customizable as we have a huge database of Liposome Drug Delivery industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.

Type analysis of Liposome Drug Delivery market.

Liposomal Doxorubicin 

The Liposomal Doxorubicin segment Revenue will be USD 3,025.75 Million by 2028.

Liposomal doxorubicin is also known as Caelyx or Myocet. It is a chemotherapy medicine which is made up of doxorubicin (Adriamycin) and a fatty coating called a liposome. Liposomal doxorubicin is used to treat cancers such as breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma. Doxorubicin enclosed in a closed lipid sphere is known as liposomal doxorubicin (liposome). These spheres prolong the time of doxorubicin in the circulation, allowing more of the medicine to reach cancer cells. In most of the cases, this drug is administered intravenously

Liposomal Amphoteracin B

Liposomal Amphoteracin B (LAmB) is an amphotericin B formulation. It can be used to combat a variety of medically relevant parasitic fungal diseases. LAmB is licensed in many countries for the treatment of invasive fungal infections and is used against clinically relevant yeasts and moulds such as Candida spp., Aspergillus spp., and filamentous moulds such as Zygomycetes. Liposomal Amphoteracin B is often utilized in individuals who are unable to tolerate or respond to standard amphotericin therapy. This medication comes in the form of an injection that can be injected into a vein. The drug assist in the prevention of fungus growth.

Liposomal Paclitaxel

Paclitaxel is a very effective cancer treatment that is used to treat ovarian, breast, lung, pancreatic, and other malignancies. Liposomal paclitaxel is a liposome-encapsulated paclitaxel medication. Liposomes can increase the solubility of paclitaxel and prolong its activity in vivo as a novel drug carrier. It offers equal anticancer activity than traditional paclitaxel while reducing toxicity and improving bioavailability.

Others

Several other types of liposomal drug deliveries include liposomal nystatin, liposomal vincristine, Liposomal cisplatin, liposomal retinoic, liposomal amikacin, and many others are available in the market. Some of these medications are still being tested in clinical trials. Liposomal nystatin is a polyene antifungal drug based on lipids. It is made up of nystatin mixed with dimyristoyl phosphotidyl choline and dimyristoyl phosphotidyl glycerol in liposomes. The in vitro activity of nystatin is preserved when it is integrated into liposomes. Similarly, Amikacin liposome is an antibiotic used to treat individuals with Mycobacterium Avium Complex (MAC) lung illness which has few or no other alternatives for therapy. Amikacin liposome is a kind of antibiotic that is used in conjunction with other antibiotics.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Liposome Drug Delivery Industry. Request a Free Sample PDF!

Liposome Drug Delivery Market, by application

Fungal Infection Therapy

The Fungal Infection Therapy segment Revenue in Liposome Drug Delivery will be USD 2,446.39 Million by 2028.

Liposomes are used to treat fungal infections. In critically immunocompromised patients, such as organ and bone marrow transplant recipients, opportunistic pathogen infections, mostly caused by Candida and Aspergillus spp., can be dangerous. Liposomal antifungal medicines have been demonstrated to be effective in several tests. These liposomal medicines have a broad antifungal range and a low risk of developing resistance. Liposomal Amphoteracin B is one of an antifungal medication that employs the liposomal drug delivery technology.

Cancer Tumor Therapy

Cancer has been a major source of concern in recent years because it is the leading cause of death. Chemotherapy is presently the most extensively used cancer treatment; yet, it has several drawbacks. Several liposomal carriers have been created or are undergoing clinical trials to circumvent this issue. Liposomes have been proposed as a good choice for drug delivery and cancer therapy in nanomedicine due to their capacity to retain medicines with varying physical and chemical properties. Liposomes can improve the sensitivity, specificity, and persistence of anti-malignant cell agents in the body, and can be used in nanomedicines to great effect.

Others

Liposomes are also employed in heavy metal chelation treatment, membrane research, cosmetics, lung disorders, and other applications. Liposomes are utilized in cosmetic formulation as a delivery route for active components in cosmetic products to reach the deeper layers of the epidermis. As a result, chemical penetration through the 'polar and lipid' channels is improved. Similarly, liposomal medication delivery by inhalation provides particular benefits in the treatment of respiratory disorders. 

Several medications' inhalable liposomes are now being tested in the lungs for a variety of indications

The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Liposome Drug Delivery market report 2023 Edition by contacting our team.

North America Liposome Drug Delivery Market Analysis:

North America has a significant market share of the liposome drug delivery market. This is attributed to the rising research and development activities in pharmaceutical industry across North America due to the rising chronic illness. According to the data from the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry in the United States spent around 21% of global revenues on R&D in 2020 while the number in 2019 and 2018 was approximately 19%.

Region-wise, the market is analyzed across: (In case you wish to acquire a specific region or any country data then please contact us)

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!

Company Profile

Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The company’s primary areas of focus include viral diseases, inflammatory diseases, and oncology. It develops a wide range of medicines used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. The products offered by company are AmBisome, Atripla, Biktarvy, Complera, Cayston, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Lexiscan, Macugen, Odefsey and others. 

Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a provider of non-opioid pain management and regenerative health solutions. The company develops pharmaceutical products, based on its proprietary multivesicular liposome (pMVL) drug delivery technology, for use in hospitals and ambulatory surgery centers.

The products offered by company are EXPAREL (bupivacaine liposome injectable suspension), iovera, Proprietary multivesicular liposome (pMVL) and ZILRETTA.

Top Companies Market Share in Liposome Drug Delivery Industry: (In no particular order of Rank)

• Takeda Pharmaceutical
• Novartis AG
• Luye Pharma Group
• IPSEN Pharma
• Celsion Corporation
• Gilead Sciences Inc.
• Astellas Pharma
• Acrotech Biopharma Inc.
• Johnson & Johnson Services Inc.
• Pacira Pharmaceuticals
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables..